C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys New Position in Exact Sciences Co. (NASDAQ:EXAS)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,508 shares of the medical research company's stock, valued at approximately $478,000.

Other large investors have also modified their holdings of the company. Thompson Investment Management Inc. lifted its stake in shares of Exact Sciences by 17.8% in the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after purchasing an additional 36,505 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of Exact Sciences by 1,153.2% in the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company's stock valued at $12,388,000 after purchasing an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. lifted its stake in shares of Exact Sciences by 67.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company's stock valued at $1,994,000 after purchasing an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new position in shares of Exact Sciences in the 3rd quarter valued at $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Exact Sciences by 59.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company's stock valued at $22,868,000 after buying an additional 125,192 shares during the period. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Upgrades and Downgrades

EXAS has been the topic of several research analyst reports. Robert W. Baird cut their price objective on Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Craig Hallum cut their price objective on Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. The Goldman Sachs Group cut their price objective on Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Piper Sandler cut their price objective on Exact Sciences from $85.00 to $75.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Finally, Jefferies Financial Group boosted their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $72.76.

Exact Sciences Stock Down 2.5 %

Shares of NASDAQ:EXAS traded down $1.28 on Monday, hitting $49.31. 2,248,133 shares of the company's stock were exchanged, compared to its average volume of 2,230,711. The firm's 50-day moving average is $55.90 and its 200 day moving average is $60.23. The company has a market capitalization of $9.13 billion, a PE ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.